News of Note—GlaxoSmithKline’s Mosquirix, Emergent BioSolutions and more

In this week's news of note, a pilot study of GSK’s malaria vaccine, Mosquirix, has been delayed. (Pixabay)

Here is some other vaccine news of note for the week:

> Stakeholders are still navigating the complex planning process for a three-country pilot study of GlaxoSmithKline’s Mosquirix. Financial Times article

> Emergent BioSolutions got approval to introduce its anthrax vaccine, BioThrax, in Italy, Poland, the U.K., the Netherlands and France. Washington Business Journal article


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> CDC Director Robert Redfield divested stock in Baltimore vaccine company Profectus BioSciences before taking on the CDC job. The Washington Post article

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.